NEUROPACE, INC. NPCE 深 滬
等待開盤 12-24 09:30:00 美东时间
16.39
-0.170
-1.03%
華盛通- 最 高16.46
- 今 開16.40
- 成交量 10.63万股
- 最 低 15.98
- 昨 收 16.56
- 總市值 5.42亿
- 52周最高 18.975
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 7.5625
- 委 比 85.37%
- 總股本 3308.15万
- 歷史最高 27.38
- 量 比 0.40
- 振 幅 2.90%
- 歷史最低 1.22
- 每 手 1
- 風險率 2.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NeuroPace Submits Premarket Approval Supplement Application To FDA For Expansion Of Labeled Indication For RNS System
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S.
12-17 21:04
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
12-17 10:46
UBS Maintains Buy on NeuroPace, Raises Price Target to $22
UBS analyst Priya Sachdeva maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price target from $18 to $22.
12-16 22:27
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
NeuroPace Presents Preliminary 18-Month Safety And Effectiveness Results From Ongoing NAUTILUS1 Trial Evaluating RNS System As Adjunctive Therapy For Treatment Of ASM Resistant IGE With GTC Seizures, At AES Meeting
-- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) ---- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting
12-08 21:10
电话会总结 ｜ NeuroPace(NPCE)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据NeuroPace业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收2,740万美元，同比增长30% - RNS系统营收2,260万美元，同比增长31% - Dixie产品营收约400万美元，同比增长8% - 研究服务营收约77万美元 **盈利能力：** - 毛利率77.4%，较去年同期73.2%显著提升，较上季度77.1%小幅上升 - RNS系统毛利率保持在80%以上的强劲水平 - 调整后EBITDA首次转正至10万美元，去年同期为负160万美元，上季度为负350万美元 **净利润：** - 净亏损350
11-10 12:10
美股牛股 | Solid Power飙升超51%！与宝马及三星SDI合作推进全固态电池技术商业化；Lemonade涨超34%
Solid Power飙升超51%！与宝马及三星SDI合作推进全固态电池技术商业化；Lemonade涨超34%，Q3业绩大幅超预期并上调业绩指引>>
11-06 15:10
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points...
11-06 00:56
Wells Fargo Maintains Overweight on NeuroPace, Raises Price Target to $16
Wells Fargo analyst Vik Chopra maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $15 to $16.
11-05 23:16
